Diplomat Specialty Pharmacy® and Diplomat Specialty Infusion Group® are joining the Optum® family.
To learn more about what this means for you, visit our FAQ pages:
HIZENTRA®
Hizentra®FDA INDICATION: Primary immunodeficiency disease (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP) Package Insert
FORM: Liquid
DISTRIBUTOR: CSL Behring
ROUTE OF ADMINISTRATION: Subcutaneous
PH (AFTER RECONSTITUTION): 4.6–5.2
CONCENTRATION: 20%
IGA CONTENT: ≤50 μg/mL
% IGG: ≥98%
NA CONTENT: Trace amounts
DILUENT: N/A
OSMOLALITY (MOSM/L): 380 mOsmol/kg
INITIAL INFUSION RATE: Not for intravenous administration. Avoid injection into blood vessel. Injection sites: abdomen, thighs, upper arms, or lateral hip. Manufacturer recommends 15 mL volume per infusion site at a max rate of 50 mL/hr/site by infusion pump.
SUGAR CONTENT: No added sugars
SHELF LIFE: 30 months
STORAGE REQUIREMENTS: Store at room temperature up to 25°C (77°F). Do not freeze. Protect from light.
PATIENT SUPPORT/ASSISTANCE PROGRAMS: CSL Behring Patient Assistance Program, CSL Behring Assurance Program
OTHER WEBSITES: TreatingPI, IgIQ, hizentra.com